soul trial oral semaglutide cardiovascular outcomes results 2025 2024 nejm 💥Soul study group recently shared semaglutide soul trial oral cardiovascular

The type III ANOVA analysis via Satterthwaites degrees of freedom was performed using the R package lmerTest [47] to assess the significance of the main effects, whereas significant relationships were further explored via estimated marginal means analysis using the package emmeans V1.11.1 [48], thus, a Tukey-adjusted contrasts pair wise comparison was also carried out

The Trellis vs

:

Semaglutide and tirzepatide have demonstrated weight reductions of 10 to 20 percent in many patients

Real-world outcomes: According to a 72-week phase 3b trial, adults with obesity (but without diabetes) treated with tirzepatide were significantly more likely to lose at least 10% or 15% of their body weight than those treated with semaglutide

many users inject AOD-9604 fasted in the morning